Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IPO Year: 2010
Exchange: NASDAQ
Website: ironwoodpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $5.00 | Market Perform | Leerink Partners |
| 8/8/2024 | $12.00 → $4.00 | Overweight → Equal Weight | CapitalOne |
| 1/17/2024 | $21.00 | Buy | Craig Hallum |
| 12/14/2023 | $20.00 | Overweight | Wells Fargo |
| 11/9/2023 | $21.00 | Buy | Jefferies |
| 9/28/2023 | $22.00 | Mkt Outperform | JMP Securities |
| 9/2/2022 | $15.00 | Overweight | CapitalOne |
| 4/22/2022 | $16.00 | Overweight | Piper Sandler |
| 10/12/2021 | $13.00 → $14.00 | Equal-Weight | Morgan Stanley |
| 7/16/2021 | $11.00 → $12.00 | Equal-Weight | Morgan Stanley |
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and red
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website for 1 year following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
– New safety and tolerability data show high treatment compliance with apraglutide, low incidence of injection site reactions and adverse events associated with GI tolerability – – Findings reinforce the clinical profile of once-weekly apraglutide; Ironwood expects to complete U.S. regulatory submission in Q1 2025 – – One apraglutide poster recognized as presidential poster recipient – – New linaclotide data shed light on treatment outcomes across patient demographics – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgr
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 2:15 p.m. ET at the Encore Boston Harbor. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website for 1 year following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for
– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its second quarter 2024 results and recent business performance. "We continued to make progress across our portfolio in the second quarter," said Tom McCourt, chief executive off
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, August 8, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 22, 2024. To listen
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood's website for 1 year following the conference
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li
– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its second quarter 2024 results and recent business performance. "We continued to make progress across our portfolio in the second quarter," said Tom McCourt, chief executive off
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, August 8, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 22, 2024. To listen
– Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) – – Reported positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease (SR GI aGVHD) – – LINZESS® (linaclotide) EUTRx prescription demand growth of 10% year-over-year – – Revises FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its first quarter 2024 results and recent business performance. "In the
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 3416473. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting Thursday, May 9, 2024 at ap
– Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations – – Apraglutide also showed a clinically meaningful improvement at week 24, with patients achieving at least one day off PS per week – – Apraglutide was generally well-tolerated, and the safety profile was consistent with previously-reported studies of apraglutide in this patient population – – Ironwood to submit new drug application and other regulatory filings for apraglutide as a once-weekly GLP-2 analog for use in adult patients with SBS who are dependent on PS – – Ironwood to host conference
– LINZESS® (Iinaclotide) 2023 U.S. net sales of $1.1 billion, an increase of 7% year-over-year, driven by EUTRx prescription demand growth of 10% year-over-year – – 2023 Ironwood revenue of $443 million, driven primarily by $430 million in U.S. LINZESS collaboration revenue – – Continues to expect topline results from the STARS Phase III study of apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF) in March of 2024 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2023 results and recent business performance. "In 2023, we made important progress toward realizing our vision to
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (647) 495-7514 (international) using conference ID number and event passcode 1057375. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting Thursd
– LINZESS® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase of 7% year-over-year – – Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC) – – Expects topline data for the Phase II study of CNP-104 in primary biliary cholangitis (PBC) in the third quarter of 2024 – – Maintains Full Year 2023 Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2023 results and recent business performance. "We are proud of the progress we
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
SCHEDULE 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwood's Leadership Team and oversee the company's Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "John's deep legal experience and proven track record, in particular his experience at highly focused healthcare companies, arm him with invaluable expertise that will strongly benefit Ironwood by helping accelerate our business priorities and reinforce our efforts to make a difference for people l
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood’s Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors. Ironwood also announced that Gina Consylman plans to step down as senior vice president and chief financial officer, effective July 2, 2021, in order to pursue another leadership opportunity at a rare disease biotechnology company. Ms. Consylman’
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
– LINZESS® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – – GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents – – Maintaining full year 2021 financial guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today provided an update on its first quarter 2021 results and recent business performance. "We are off to a solid start to the year, as LINZESS continued the strong momentum we saw in 2020," said Tom M
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent. “We are excited to welcome Jay to Ironwood’s Board. Jay is a recognized leader within our industry with nearly three decades of expertise as an accomplished public company CEO and senior executive,” said Julie McHugh, chair of Ironwood’s Board. “We look forward to leveraging Jay’s deep expertise as we seek to further our mission to adva
SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
Leerink Partners initiated coverage of Ironwood Pharma with a rating of Market Perform and set a new price target of $5.00
CapitalOne downgraded Ironwood Pharma from Overweight to Equal Weight and set a new price target of $4.00 from $12.00 previously
Craig Hallum initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00
Wells Fargo initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $20.00
Jefferies initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00
JMP Securities initiated coverage of Ironwood Pharma with a rating of Mkt Outperform and set a new price target of $22.00
CapitalOne initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $15.00
Piper Sandler initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $16.00
Morgan Stanley reiterated coverage of Ironwood Pharmaceuticals with a rating of Equal-Weight and set a new price target of $14.00 from $13.00 previously
Morgan Stanley reiterated coverage of Ironwood Pharmaceuticals with a rating of Equal-Weight and set a new price target of $12.00 from $11.00 previously